Skip to main content
. 2021 Aug 19;19(8):e3001387. doi: 10.1371/journal.pbio.3001387

Fig 5. Gal-9 binds CD44 on T cells and enhances T-cell activation.

Fig 5

(A) Images showing the expression of CD44 and Gal-9 on the surface of T cells. (B) Cumulative data showing percent colocalization of Gal-9 with CD44 and CD137. (C) Percent of Gal-9+ T cells in the presence or absence of recombinant Gal-9 following in vitro incubation. (D) Percent CD44 clustering in the presence and absence of Gal-9. (E) Representative plots and (F) cumulative data showing percentages of CD4+ T cells expressing CD38 or (G) HLA-DR following stimulation with anti-CD3/CD28 antibodies in the presence of exogenous Gal-9 (1,000 pg/ml) and/or Gal-9 and anti-CD44 and anti-CD137 antibodies. (H) Representative plots and (I) cumulative data showing percentages of CD8+ T cells expressing CD38 or (J) HLA-DR following stimulation with anti-CD3/CD28 antibodies in the presence of exogenous Gal-9 (1,000 pg/ml) and/or Gal-9 and anti-CD44 and anti-CD137 antibodies. (K) Representative plots and (L) cumulative data showing phospho-LCK (Y505) in CD4+ and (M) CD8+ T cells in the absence and presence of Gal-9 (1,000 pg/ml). The underlying data can be found in S1 Data. Gal-9, Galectin-9.